SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute…
NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the…